Colocation of Tpm3.1 and myosin IIa heads defines a discrete subdomain in stress fibres.
APEX
Actin filament organisation
Myosin II
Tropomyosin
Journal
Journal of cell science
ISSN: 1477-9137
Titre abrégé: J Cell Sci
Pays: England
ID NLM: 0052457
Informations de publication
Date de publication:
08 08 2019
08 08 2019
Historique:
received:
13
12
2018
accepted:
06
07
2019
pubmed:
25
7
2019
medline:
10
7
2020
entrez:
24
7
2019
Statut:
epublish
Résumé
Co-polymers of tropomyosin and actin make up a major fraction of the actin cytoskeleton. Tropomyosin isoforms determine the function of an actin filament by selectively enhancing or inhibiting the association of other actin binding proteins, altering the stability of an actin filament and regulating myosin activity in an isoform-specific manner. Previous work has implicated specific roles for at least five different tropomyosin isoforms in stress fibres, as depletion of any of these five isoforms results in a loss of stress fibres. Despite this, most models of stress fibres continue to exclude tropomyosins. In this study, we investigate tropomyosin organisation in stress fibres by using super-resolution light microscopy and electron microscopy with genetically tagged, endogenous tropomyosin. We show that tropomyosin isoforms are organised in subdomains within the overall domain of stress fibres. The isoforms Tpm3.1 and 3.2 (hereafter Tpm3.1/3.2, encoded by
Identifiants
pubmed: 31331962
pii: jcs.228916
doi: 10.1242/jcs.228916
pii:
doi:
Substances chimiques
Protein Isoforms
0
TPM3 protein, human
0
Tropomyosin
0
Nonmuscle Myosin Type IIA
EC 3.6.1.-
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2019. Published by The Company of Biologists Ltd.
Déclaration de conflit d'intérêts
Competing interestsE.C.H. and P.W.G. are directors and shareholders in TroBio Therapeutics, a company that is commercialising anti-tropomyosin drugs for the treatment of cancer and their labs receive funding from TroBio to evaluate anti-tropomyosin drug candidates. J.C.M.M., N.S.B., M.L.C., A.B., R.M.W., N.A. and R.G.P. have no competing interests.